Stock ZEG ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AstraZeneca PLC Xetra

Equities

ZEG

GB0009895292

Market Closed - Xetra
Other stock markets
 11:35:32 2024-06-14 am EDT 		5-day change 1st Jan Change
148.7 EUR +1.19% Intraday chart for AstraZeneca PLC +0.30% +21.79%
Jun. 14 European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
Jun. 13 Tesla, Inc. : Musk moves a step closer to the $56 billion prize and the transfer of Tesla's headquarters to Texas Our Logo

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • With a 2024 P/E ratio at 22 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ASTRAZENECA PLC Stock AstraZeneca PLC
+21.79% 246B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
C+
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
A+
NOVARTIS AG Stock Novartis AG
+11.95% 218B
B-
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
C+
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. ZEG Stock
  5. Ratings AstraZeneca PLC